Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NaCl-saline placebo Clear all
Completed Phase 4 Interventional Results available

Preventing Propofol-associated Injection Pain

NCT00864682
View directory record Official record
Conditions
Pain
Interventions
Saline, Lidocaine / propofol admixture, lidocaine pretreatment
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479
View directory record Official record
Conditions
Systemic Allergic Reaction
Interventions
Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 14, 2026, 2:45 PM EDT
Recruiting Phase 2 Interventional

Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department

NCT07868913
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine Injectable Solution, Placebo Injection, Crisis Response Plan, Safety Planning
Drug · Other · Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Fort Hood, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Anakinra to Prevent Post-infarction Remodeling

NCT00789724
View directory record Official record
Conditions
ST Segment Elevation Acute Myocardial Infarction
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 14, 2026, 2:45 PM EDT
Active, not recruiting Phase 3 Interventional

Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain

NCT05037123
View directory record Official record
Conditions
Chronic Postsurgical Pain
Interventions
Continuous ketamine infusion, Ketamine + Saline, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 14, 2026, 2:45 PM EDT
Withdrawn Phase 1 Interventional

Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response

NCT02823106
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Verapamil and Citicoline, Placebo
Drug · Other
Lead sponsor
Justin Fraser
Other
Eligibility
18 Years to 101 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

NCT02586233
View directory record Official record
Conditions
Acute Ischemic Stroke, Thrombotic Disease
Interventions
DS-1040b, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Mobile, Alabama • Los Angeles, California • Colorado Springs, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

NCT03473002
View directory record Official record
Conditions
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions
Placebo, SeVRSV Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 14, 2026, 2:45 PM EDT
Terminated Phase 1 Interventional

Ketamine and Magnesium in Post-operative Pain Control in Patients Treated With Opioids

NCT02940509
View directory record Official record
Conditions
Chronic Pain
Interventions
Ketamine plus Magnesium sulfate, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects

NCT04075175
View directory record Official record
Conditions
Diphtheria
Interventions
S315, 0.9% Sodium Chloride (NaCl)
Drug
Lead sponsor
MassBiologics
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

NCT01059565
View directory record Official record
Conditions
Cystic Fibrosis, Burkholderia Infections
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 14, 2026, 2:45 PM EDT
Not listed Not applicable Interventional

"Platelet Rich Plasma for the Management of Post-Viral Olfactory Dysfunction.

NCT05666492
View directory record Official record
Conditions
Olfactory Disorder, Olfaction Disorders
Interventions
Platelet rich plasma, Saline
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever

NCT02116205
View directory record Official record
Conditions
Hemorrhagic Fever With Renal Syndrome
Interventions
HTNV/PUUV DNA vaccine, Placebo, TriGrid Delivery System (TDS)
Biological · Device
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 49 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

NCT02112656
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
ThermoDox, Dummy infusion
Drug
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 14, 2026, 2:45 PM EDT
Terminated Not applicable Interventional Results available

Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED

NCT00655642
View directory record Official record
Conditions
Nausea
Interventions
Ondansetron, Metoclopramide, Promethazine, Normal Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 14, 2026, 2:45 PM EDT
Not yet recruiting Phase 2 Interventional

Evaluating Intranasal Oxytocin (TNX-1900) for Pain Relief and Recovery After Pituitary Surgery

NCT07730294
View directory record Official record
Conditions
Pain, Pituitary Surgery
Interventions
Oxytocin (Low dose), Oxytocin (High dose), Placebo (saline)
Drug
Lead sponsor
Yale University
Other
Eligibility
30 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 14, 2026, 2:45 PM EDT
Active, not recruiting Phase 3 Interventional

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

NCT04468659
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Interventions
Lecanemab, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

NCT02852005
View directory record Official record
Conditions
HIV Infections
Interventions
MVA/HIV62B vaccine, AIDSVAX B/E vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women

NCT03640754
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
G-CSF, Placebo/Saline
Biological · Other
Lead sponsor
MenoGeniX, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

NCT02296541
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 4 Interventional Results available

Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease

NCT02630966
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Nashville, Tennessee • Southlake, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 14, 2026, 2:45 PM EDT
Terminated Phase 1Phase 2 Interventional

Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing

NCT03117166
View directory record Official record
Conditions
Pain
Interventions
lidocaine, Placebo
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 14, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

NCT03918629
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
1,994 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
52
States / cities
Athens, Alabama • Huntsville, Alabama • Chandler, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 14, 2026, 2:45 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The RECAP2 Study: Midazolam and Psilocybin

NCT06692192
View directory record Official record
Conditions
Psilocybin
Interventions
Psilocybin, Midazolam, Saline
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 14, 2026, 2:45 PM EDT